Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

November 14, 2019November 14, 2019

Vertex Reaches Agreement for CF Medications in Northern Ireland and Wales

cystic fibrosis, News

The Regional Pharmaceutical Procurement Service in Northern Ireland and the National Health Service (NHS) Wales have reached an agreement with Vertex Pharmaceuticals that will allow people with cystic fibrosis ... Read more

October 24, 2019October 25, 2019

Cystic Fibrosis Foundation Applauds FDA Approval of Trikafta

cystic fibrosis, News

The Cystic Fibrosis Foundation (CFF) is celebrating the United States Food and Drug Administration’s decision to approve Trikafta. The therapy — a triple combo based on elexacaftor, tezacaftor, and ivacaftor, which is being ... Read more

October 23, 2019October 23, 2019

Europe’s CHMP Issues Positive Opinion on Kalydeco Use in Infants

cystic fibrosis, News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the use of Kalydeco (ivacaftor) in infants ages ... Read more

October 16, 2019October 16, 2019

Chelsea Financial Services Supporting Boomer Esiason Foundation, CF Research at NYC Marathon

cystic fibrosis, News

John Pirozzi, a representative of Chelsea Financial Services, will participate in the TCS New York City Marathon to raise money for cystic fibrosis research, the company announced. Pirozzi is ... Read more

October 10, 2019October 10, 2019

FDA Designates Vast’s BIOC11 a Qualified Infectious Disease Product

cystic fibrosis, News

The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for the treatment of people with cystic fibrosis (CF) who have chronic ... Read more

October 8, 2019October 8, 2019

Experts Highlight Obstacles in Delivering New CF Therapies

cystic fibrosis

Care for cystic fibrosis (CF) has improved substantially in recent decades, but there are still challenges ahead, particularly in ensuring that all patients have access to the best available ... Read more

September 30, 2019September 30, 2019

Public Encouraged to Vote for 2 Students with CF to Receive $22K AbbVie Scholarships

cystic fibrosis, News

Voting for two students to receive two scholarships — valued at $22,000 each — is now open to the public until Oct. 9, pharmaceutical company AbbVie has announced. After ... Read more

September 27, 2019September 27, 2019

AzurRx BioPharma Announces Promising Results from Trial Testing MS1819 for EPI in CF Patients

cystic fibrosis, News

The investigational therapy MS1819 showed positive safety results in a Phase 2 clinical trial for the treatment of exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF), AzurRx BioPharma ... Read more

September 13, 2019September 13, 2019

New Agreement in Scotland Grants CF Patients Access to Orkambi and Symkevi

News

A new agreement will give people in Scotland with cystic fibrosis access to the CF combination treatments Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) through the country’s health system, according to ... Read more

September 10, 2019September 10, 2019

Drexel Study to Look at Tailored ‘Talk’ Therapy in Helping Ease Depression and Anxiety in CF Patients

cystic fibrosis, News

How well Acceptance and Commitment Therapy (ACT), or tailored “talk” therapy that can be delivered via telemedicine, helps people with cystic fibrosis (CF) cope with mental health issues will ... Read more

Pin It on Pinterest